ClinicalTrials.gg
RecruitingNCT07292402Updated Dec 23, 2025

JSKN022 in Subjects With Advanced Malignant Solid Tumors

A Phase 1 interventional study of JSKN022 in Advanced Malignant Solid Tumors, sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Jiangsu Alphamab Biopharmaceuticals Co., Ltd (part of Alphamab Oncology) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
225
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to learn if drug JSKN022 is safe to treat patients with advanced malignant solid tumors. It will also learn about the pharmacokinetic/ pharmacodynamic profiles and preliminary antitumor activity of drug JSKN022.

Read the detailed description

This is a Phase I, open-label, multi-center, first-in-human (FIH) clinical trial designed to evaluate the safety, tolerability, pharmacokinetic (PK)/pharmacodynamic (PD) profiles, and antitumor activity of JSKN022 in patients with advanced malignant solid tumors.

Patients to be enrolled are with advanced unresectable or metastatic epithelial-derived malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), or be intolerant to standard treatment, or have no access to standard treatment.

The primary objective of the study is to evaluate the safety and tolerability of JSKN022 in patients with advanced malignant solid tumors and to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of JSKN022.

02

Conditions studied

  • Advanced Malignant Solid Tumors

Keywords

  • JSKN022
  • PD-L1
  • ITGB6
  • Antibody-Drug Conjugates
03

In context

Lead sponsor

Jiangsu Alphamab Biopharmaceuticals Co., Ltd is the lead sponsor of 38 studies on the registry; 16 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate and sign the form.
  2. Age ≥ 18 years old, male or female.
  3. performance status (ECOG PS) score of 0 or 1.
  4. Expected survival ≥ 3 months.
  5. or cytologically confirmed malignant solid tumors confirmed by histology and/or cytology, who have failed previous standard treatment (disease progression), are intolerant to standard treatment, or have no access to standard treatment.
  6. At least one at baseline according to 1.1 criteria.
  7. Adequate organ function.
  8. Agree to provide Recently archived or fresh tumor tissue samples.
  9. Female subjects of or male subjects whose partners are of childbearing potential agree to use effective measures.
  10. Female subjects of childbearing potential must have a negative serum/urine pregnancy test within 7 days before the first dose.
  11. Be able and willing to comply with the visits, treatment plans, laboratory tests, and other study-related procedures specified in the study protocol.
  12. Adequate of previous therapy before the first dose.

Exclusion criteria

Exclusion Criteria:

  1. Complicated with other malignant tumors within 5 years before the first dose, except for tumor types that have achieved clinical cure through local treatment with extremely low recurrence risk or tumor types with disease-free survival ≥ 5 years after radical treatment and extremely low recurrence/ risk.
  2. History of brainstem, meningeal metastasis, spinal cord metastasis or compression, or carcinomatous meningitis; presence of active .
  3. Screening imaging shows tumor invasion, compression, or occurrence in surrounding important organs or risk of esophagotracheal fistula or esophagopleural fistula, except those judged by the investigator and medical monitor to not affect the patient's enrollment and administration.
  4. Presence of clinically severe respiratory impairment caused by pulmonary disease complications.
  5. Presence of the risk factors related to interstitial lung disease (ILD) or non-infectious pneumonia:
  6. Presence of cardiovascular and cerebrovascular diseases or cardiovascular and cerebrovascular risk factors.
  7. Gastrointestinal abnormalities with obvious clinical manifestations.
  8. Active diseases requiring systemic treatment within the past two years.
  9. Significant serous effusion.
  10. Uncontrolled infection.
  11. Require regular or therapy.
  12. Received within 28 days before the first dose, or plan to receive live vaccines during the study period.
  13. Prior treatment with antibody-drug conjugates containing topoisomerase I inhibitors.
  14. Previous occurrence of grade ≥ 3 immune-related adverse events during immunotherapy.
  15. Toxicity of previous anti-tumor treatment has not fully or partially recovered.
  16. Known allergy to any component of the study drug, or history of severe allergic reactions to other antibody drugs.
  17. Pregnant and/or lactating women, or planning to become pregnant during the study period.
  18. Known history of mental illness, substance abuse, alcoholism, etc., or other situations that the investigator deems may affect the safety or compliance of the study drug treatment.
  19. Local or systemic diseases caused by non-malignant tumors, or diseases or symptoms secondary to tumors, which may lead to high medical risks and/or uncertainty in survival assessment, such as tumor-related leukemia reaction (white blood cell count > 20×10⁹/L), cachexia manifestations, etc.
  20. Any other previous or current diseases, treatments, or laboratory test abnormalities that the investigator deems may confuse the study results, affect the patient's full participation in the study, or participation in the study may not be in the best interest of the patient.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
225 participants (estimated)

Study arms

  • Experimental
    Dose escalation cohorts 1

    Drug: JSKN022

  • Experimental
    Dose escalation cohort 2

    Drug: JSKN022

  • Experimental
    Dose escalation cohort 3

    Drug: JSKN022

  • Experimental
    Dose escalation cohort 4

    Drug: JSKN022

  • Experimental
    Dose escalation cohort 5

    Drug: JSKN022

  • Experimental
    Dose escalation cohort 6

    Drug: JSKN022

  • Experimental
    Dose escalation cohort 7

    Drug: JSKN022

  • Experimental
    Dose escalation cohort 8

    Drug: JSKN022

  • Experimental
    Dose optimization cohort in selected tumor type 1

    Drug: JSKN022

  • Experimental
    Dose optimization cohort in selected tumor type 2

    Drug: JSKN022

  • Experimental
    Dose optimization cohort 3 - other advanced epithelial malignant tumors cohort

    Drug: JSKN022

Interventions

  • DrugJSKN022

    JSKN022 administered intravenously at selected dose levels according to protocol

06

What researchers measure

Primary outcomes

  1. Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc (Safety and tolerability of JSKN-022).

    Frequency and severity of treatment-emergent adverse events (TEAEs), treatment-related adverse events (TRAEs), serious adverse events (SAEs), etc.; abnormalities in physical examinations, laboratory tests, electrocardiograms, and other safety assessments.

    Time frame: From the first dose to 30 days after the last dose or until initiation of new anti-tumor treatment, whichever comes first.

  2. Incidence of dose-limiting toxicity (DLT) in each dose group

    Time frame: 21 days from the first dose

  3. Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of JSKN022.

    Time frame: Up to 24 months

Secondary outcomes

  1. Objective response rate (ORR)

    The proportion of subjects who achieve confirmed complete response (CR) or partial response (PR) as assessed by RECIST v1.1. ORR analysis will be based on the EAS set, with the proportion of subjects achieving objective response and the Clopper-Pearson exact 95% CI calculated.

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months.

  2. Duration of response (DoR)

    Defined as the time from the first documented evidence of response (PR or CR) to the first documented evidence of progressive disease (PD) or death from any cause in subjects with confirmed response (RECIST v1.1, PR or CR). For subjects without documented progression or death, DoR will be censored at the time of the last adequate tumor assessment. DoR analysis will be performed on subjects achieving CR or PR, with the median duration of response and 95% CI estimated using the Kaplan-Meier method.

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed up to 24 months.

  3. Disease control rate (DCR)

    The proportion of subjects who achieve confirmed CR, PR, or SD as assessed by RECIST v1.1. DCR analysis will be based on the EAS set, with the proportion of subjects achieving disease control and the Clopper-Pearson exact 95% CI calculated.

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months.

  4. Clinical benefit rate (CBR)

    The proportion of subjects who achieve confirmed CR, PR, or stable disease (SD) lasting more than 6 months as assessed by RECIST v1.1. CBR analysis will be based on the EAS set, with the proportion of subjects achieving clinical benefit and the Clopper-Pearson exact 95% CI calculated.

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed at approximately 12 months.

  5. Progression-Free Survival (PFS)

    Defined as the time from the first administration of the study drug to the first documentation of PD or death from any cause. PFS analysis will be based on the SAS set, with the median progression-free survival and 95% CI estimated using the Kaplan-Meier method. The 3-month, 6-month, 9-month, and 12-month progression-free survival rates and their 95% CIs will be calculated, and progression-free survival curves will be plotted.

    Time frame: From the first study drug dose, until: disease progression per RECIST 1.1; initiation of new anti-tumor treatment; withdrawal of informed consent; death; loss to follow-up; or study termination, whichever comes first. Assessed up to 24 months.

  6. 6-Month and 12-Month Overall Survival Rates

    Defined as the probability of survival 6 months and 12 months after the first administration of the study drug, respectively. Analysis of 12-month survival rate will be based on the SAS set, with the 12-month survival rate and 95% CI estimated using the Kaplan-Meier method.

    Time frame: From the first administration of the study drug until the death. Assessed up to 24 months.

  7. Incidence of anti-drug antibodies (ADA), antibody titers, and incidence of neutralizing antibodies (Nab, if applicable).

    Time frame: Up to 24 months

  8. Maximum concentration (Cmax) of JSKN022

    Maximum concentration (Cmax) of JSKN022

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  9. Time to maximum concentration (Tmax) of JSKN022

    Time to maximum concentration (Tmax) of JSKN022

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  10. Trough concentration (Ctrough) of JSKN022

    Trough concentration (Ctrough) of JSKN022

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  11. Area under the concentration-time curve of JSKN022

    Area under the concentration-time curve of JSKN022

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  12. Volume of distribution (V) of JSKN022

    Volume of distribution (V) of JSKN022

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  13. Elimination half-life (t1/2) of JSKN022

    Elimination half-life (t1/2) of JSKN022

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

  14. Clearance (CL) of JSKN022

    Clearance (CL) of JSKN022

    Time frame: From the enrollment until the end of study. Assessed up to 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Aug 2027, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Dec 18, 2025
StartActual
Oct 23, 2025
Primary completionEst.
Aug 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07292402
Responsible party
Sponsor
First posted
Dec 18, 2025
Start date
Oct 23, 2025
Primary completion
Aug 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Dec 23, 2025

Study contacts

Ruihua Xu, Dr.
Contact
ruihxu@163.com
086-020-87343468

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion